Global Pharmaceutical & Biotechnology Outlook 2011
Outlook-11’ is an extensive, yet conclusive research work that encompasses a comprehensive, historical and forward looking analysis of ~80 small and large cap US, EU, Japan and ROW companies – formulated with an aim to facilitate strategic and long term investment decision making of senior management. Outlook-11’ has been tailored to deliver more meaningfully in the current economic scenario.
MP Advisors integrated top-bottom and bottom-up research methodology spots business models which are valued to a lesser extent as compared to some of the 'popular' business models. The company capsules’ of over 80 bio-pharmaceuticals elucidate the financial and strategic model they follow, the pros and cons about existing and new products, growth strategies for the future, and their key milestones.
The Global Pharmaceutical Model is changing. Major pharmaceutical companies continue to under-perform in a market constrained by patent expiry, generic competition and a lack of new blockbuster drugs. There are signs of improvement, with the outcome of new clinical trials and new launches expected to reshape market dynamics.
Our analysts have studied ~200 clinical and regulatory upcoming events, changing dynamics in generic players on back of dozens of Para IV, new found love by Large cap innovators in generics and emerging markets beyond BRIC, and dominance of Biologics in R&D pipeline etc. Some of the key findings from Outlook 2011 to share are:
The pleasant shock of 2011 is that fresh peak sales generation from anticipated approvals; Outlook-2011 reveals how new product approvals will compensate for the next burst of patent expiries by a much larger magnitude than commonly perceived.
Number of upcoming positive milestones in 2011 far exceed negative outcome milestones and ~ half a dozen of such events will bring moderate re-rating of companies which spend/invest ~ 15% of sales and ~ 40% of Operating profit in R&D and are trading at single digit PEx.
This new report makes sense of a rapidly changing pharmaceutical market and provides unparalleled insight and analysis that will enable you to seek out the capabilities that are needed for success and the companies that have those capabilities.
In the 454 page research report view at five market sections:
Rising Stars
Mature Biotech
Indian Generics
Global Pharma
Japan - Global and Emerging
For each market place the report provides a detailed sector overview and then recommends the companies that will succeed and explains why.
Each company analysis includes a detailed drug pipeline analysis with explanations of how a drug will perform in its therapy area and how the market will shape up due to competition.
MP Advisors integrated top-bottom and bottom-up research methodology spots business models which are valued to a lesser extent as compared to some of the 'popular' business models. The company capsules’ of over 80 bio-pharmaceuticals elucidate the financial and strategic model they follow, the pros and cons about existing and new products, growth strategies for the future, and their key milestones.
The Global Pharmaceutical Model is changing. Major pharmaceutical companies continue to under-perform in a market constrained by patent expiry, generic competition and a lack of new blockbuster drugs. There are signs of improvement, with the outcome of new clinical trials and new launches expected to reshape market dynamics.
Our analysts have studied ~200 clinical and regulatory upcoming events, changing dynamics in generic players on back of dozens of Para IV, new found love by Large cap innovators in generics and emerging markets beyond BRIC, and dominance of Biologics in R&D pipeline etc. Some of the key findings from Outlook 2011 to share are:
The pleasant shock of 2011 is that fresh peak sales generation from anticipated approvals; Outlook-2011 reveals how new product approvals will compensate for the next burst of patent expiries by a much larger magnitude than commonly perceived.
Number of upcoming positive milestones in 2011 far exceed negative outcome milestones and ~ half a dozen of such events will bring moderate re-rating of companies which spend/invest ~ 15% of sales and ~ 40% of Operating profit in R&D and are trading at single digit PEx.
This new report makes sense of a rapidly changing pharmaceutical market and provides unparalleled insight and analysis that will enable you to seek out the capabilities that are needed for success and the companies that have those capabilities.
In the 454 page research report view at five market sections:
Rising Stars
Mature Biotech
Indian Generics
Global Pharma
Japan - Global and Emerging
For each market place the report provides a detailed sector overview and then recommends the companies that will succeed and explains why.
Each company analysis includes a detailed drug pipeline analysis with explanations of how a drug will perform in its therapy area and how the market will shape up due to competition.
COMPANIES MENTIONED
All
All
